GeneDx Holdings (WGS) Receivables (2020 - 2026)

GeneDx Holdings (WGS) has reported Receivables for 7 consecutive years, with $81.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Receivables rose 77.63% year-over-year to $81.7 million; the TTM figure through Mar 2026 stood at $81.7 million (up 77.63% YoY), while the FY2025 annual figure was $79.9 million, up 112.42% from the prior year.
• Receivables grew to $81.7 million in Q1 2026 per WGS's latest filing, from $79.9 million in the prior quarter.
• Across five years, Receivables topped out at $81.7 million in Q1 2026 and bottomed at $470000.0 in Q4 2023.
• Historically, Receivables has averaged $41.3 million across 5 years, with a median of $44.1 million in 2022.
• Annual changes were most pronounced in 2023 — Receivables plunged 98.94% — and 2024, when it surged 7906.17%.
• GeneDx Holdings' Receivables stood at $44.1 million in 2022, then slumped by 98.94% to $470000.0 in 2023, then soared by 7906.17% to $37.6 million in 2024, then jumped by 112.42% to $79.9 million in 2025, then increased by 2.19% to $81.7 million in 2026.
• Business Quant data shows WGS's Receivables at $81.7 million in Q1 2026, $79.9 million in Q4 2025, and $60.9 million in Q3 2025.